New Metric for Predicting COVID-19 Outcomes

Advancements in COVID-19 Research

As the global community continues to confront the COVID-19 pandemic, researchers are making strides that offer clarity and hope in managing the crisis. Recently, a team from the Royal College of Surgeons in Ireland has developed a prognostic point system designed to predict COVID-19 outcomes.

Understanding the Prognostic Model

The new model for assessing the progression of COVID-19 relies on the measurement of two immune system molecules: IL-6 and IL-10. IL-6 is known for its role in causing inflammation, which can lead to symptoms such as fever and organ damage. In contrast, IL-10 functions to suppress inflammation, particularly in cases like COVID-19. By analyzing the ratio of IL-6 to IL-10 produced by individuals, the researchers were able to gauge the severity of the illness.

Study Overview

The study involved 80 randomly selected COVID-19 positive patients from hospital records. A significant 88% of these participants required oxygen support, with some in critical condition in the intensive care unit. Over a seven-day period, the researchers monitored patient clinical symptoms and collected blood samples every two days to evaluate IL-6 and IL-10 levels. The patients’ illness progression was categorized as “unchanged,” “improved,” or “declined.”

Development of the Dublin-Boston Point System

From the observations of patient symptoms and the IL-6:IL-10 ratio blood data, the researchers created the “Dublin-Boston” point system. This scoring system aims to indicate the likelihood of a patient experiencing worsening symptoms. Utilizing the Dublin-Boston score can aid in the development of therapies for patients experiencing severe COVID-19 symptoms.

Monitoring IL-6:IL-10 Ratio for Clinical Outcomes

The findings revealed a correlation between the monitoring of IL-6:IL-10 levels and patient clinical outcomes. The researchers determined that assessing the IL-6:IL-10 production every four days was optimal for accurately identifying the risk of worsening symptoms. Historically, COVID-19 patients have shown elevated IL-6 levels and reduced IL-10 levels, enabling clinicians to better understand the stage of illness.

Limitations and Considerations

Despite the structured nature of the study, it is important to note that the researchers monitored only a small patient cohort, and their findings await replication. Additionally, there are biological limitations to consider when evaluating IL-6:IL-10 ratios. While IL-6 can contribute to organ damage through inflammation, it also plays a crucial role in immune function. Consequently, medical professionals must exercise caution when designing therapies that target the IL-6:IL-10 ratio. The focus should not be solely on reducing IL-6 but rather on achieving a balanced level of both molecules in the body.

Implications of the Dublin-Boston Score

If successful, the Dublin-Boston score could enable healthcare professionals to identify the risk of mortality in COVID-19 patients at an early stage. This proactive approach could enhance patient care by ensuring timely interventions and optimizing the allocation of healthcare resources. Furthermore, the Dublin-Boston score may serve as a valuable tool in evaluating the efficacy of future treatments based on IL-6:IL-10 levels.

Author Information

Written by Melody Sayrany

References

Mcelvaney, O. J., Hobbs, B. D., Qiao, D., Mcelvaney, O. F., Moll, M., Mcevoy, N. L., … Mcelvaney, N. G. (2020). A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19. EBioMedicine, 61, 103026. doi:10.1016/j.ebiom.2020.103026

Image Credit

Image by athree23 from Pixabay